spirapril

Trade name: renormax

Small moleculeapproved

Approved

Dec 29, 1994

Spirapril (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. — NCATS

Clinical trial activity

2 trials · 6 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2

Earliest trial started Mar 1, 2000 (NCT00295542)

Timeline

1990s

  1. Dec 29, 1994

    Earliest FDA Approval

Indications

Mechanism of action

Approval history

  • approvedDec 29, 1994

Chemistry & pharmacology

Loading structure…

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2
Mol. weight
466.63 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • 1,4-dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8s-(7(r*(r*)),8r*))-
  • quadropril
  • renormax
  • renormax
  • renormax
  • renormax
  • renormax
  • renormax
  • renpress
  • sch 33844
  • sch-33844
  • sch-33844
  • sch-33844
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril
  • spirapril hcl
  • spirapril hcl
  • spirapril hcl
  • spirapril hydrochloride
  • spirapril hydrochloride
  • spirapril hydrochloride
  • spirapril hydrochloride
  • spirapril hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02817360Phase 4Feb 1, 2016Medical University of Vienna, University of Vienna
NCT00295542Phase 4Mar 1, 2000Government of Spain, University of Santiago, University of Vigo, Xunta de Galicia
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of SpainGovernment1012000
Medical University of ViennaAcademic/Hospital1112016
University of SantiagoAcademic/Hospital1012000
University of ViennaAcademic/Hospital1012016
University of VigoAcademic/Hospital1112000
Xunta de GaliciaAcademic/Hospital1012000
6 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
SandozFor profitNDA
ScheringFor profitNDA2